Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) von Morita, Kiyomi, Montalban Bravo, Guillermo, Sasaki, Koji, Bodden, Kristy R., Wang, Feng, Bose, Prithviraj, Alvarado, Yesid, Daver, Naval, Borthakur, Gautam, Ravandi, Farhad, Takahashi, Koichi, Jabbour, Elias, DiNardo, Courtney D., Pemmaraju, Naveen, Kadia, Tapan M., Ohanian, Maro, Pierce, Sherry A., Azab, Mohammad, Kantarjian, Hagop M., Garcia-Manero, Guillermo

Volltext

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) von Garcia-Manero, Guillermo, Sasaki, Koji, Montalban-Bravo, Guillermo, Bodden, Kristy R., Bose, Prithviraj, Alvarado, Yesid, Daver, Naval G., Borthakur, Gautam, Ravandi, Farhad, Takahashi, Koichi, Cortes, Jorge E., Jabbour, Elias J., Naqvi, Kiran, DiNardo, Courtney D., Benton, Christopher B., Pemmaraju, Naveen, Kadia, Tapan M., Ohanian, Maro N., Pierce, Sherry A., Kantarjian, Hagop M.

Volltext